3g5i
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | + | [[Image:3g5i.png|left|200px]] | |
| - | [[Image:3g5i. | + | |
<!-- | <!-- | ||
| Line 12: | Line 11: | ||
===Crystal Structure of the E.coli RihA pyrimidine nucleosidase bound to a iminoribitol-based inhibitor=== | ===Crystal Structure of the E.coli RihA pyrimidine nucleosidase bound to a iminoribitol-based inhibitor=== | ||
| + | |||
| + | <!-- | ||
| + | The line below this paragraph, {{ABSTRACT_PUBMED_16411753}}, adds the Publication Abstract to the page | ||
| + | (as it appears on PubMed at http://www.pubmed.gov), where 16411753 is the PubMed ID number. | ||
| + | --> | ||
| + | {{ABSTRACT_PUBMED_16411753}} | ||
==About this Structure== | ==About this Structure== | ||
| - | + | [[3g5i]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Escherichia_coli Escherichia coli]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3G5I OCA]. | |
==Reference== | ==Reference== | ||
| Line 26: | Line 31: | ||
[[Category: Glycosidase]] | [[Category: Glycosidase]] | ||
[[Category: Hydrolase]] | [[Category: Hydrolase]] | ||
| - | |||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Feb 10 17:52:56 2010'' | ||
Revision as of 18:32, 14 March 2011
Crystal Structure of the E.coli RihA pyrimidine nucleosidase bound to a iminoribitol-based inhibitor
Template:ABSTRACT PUBMED 16411753
About this Structure
3g5i is a 4 chain structure with sequence from Escherichia coli. Full crystallographic information is available from OCA.
Reference
- Muzzolini L, Versees W, Tornaghi P, Van Holsbeke E, Steyaert J, Degano M. New insights into the mechanism of nucleoside hydrolases from the crystal structure of the Escherichia coli YbeK protein bound to the reaction product. Biochemistry. 2006 Jan 24;45(3):773-82. PMID:16411753 doi:10.1021/bi0511991
- Giabbai B, Degano M. Crystal structure to 1.7 a of the Escherichia coli pyrimidine nucleoside hydrolase YeiK, a novel candidate for cancer gene therapy. Structure. 2004 May;12(5):739-49. PMID:15130467 doi:http://dx.doi.org/10.1016/j.str.2004.03.018
